Loading...

Terveystalo Oyj

OTCPK:TTAL.F
Snowflake Description

Solid track record and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TTAL.F
OTCPK
€1B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Terveystalo Oyj provides healthcare services in Finland. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
TTAL.F Share Price and Events
7 Day Returns
3.8%
OTCPK:TTAL.F
0.7%
US Healthcare
1.4%
US Market
1 Year Returns
-
OTCPK:TTAL.F
11.3%
US Healthcare
2.3%
US Market
TTAL.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Terveystalo Oyj (TTAL.F) 3.8% 3.3% -9.3% - - -
US Healthcare 0.7% 3.5% 0.1% 11.3% 38.7% 88%
US Market 1.4% 5.6% 5.7% 2.3% 44.2% 40.9%
1 Year Return vs Industry and Market
  • No trading data on TTAL.F.
  • No trading data on TTAL.F.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Terveystalo Oyj undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Terveystalo Oyj to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our calculation method for this is changing soon.

Below are the data sources, inputs and calculation used to determine the intrinsic value for Terveystalo Oyj.

OTCPK:TTAL.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.2%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:TTAL.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 7.3%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.77
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.77 (1 + (1- 20%) (41.42%))
1.025
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.02
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.025 * 7.27%)
10.18%

Discounted Cash Flow Calculation for OTCPK:TTAL.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Terveystalo Oyj is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:TTAL.F DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (EUR, Millions) 81.10 72.40 78.27 88.02 99.00
Source Analyst x3 Analyst x3 Analyst x3 Est @ 12.47% Est @ 12.47%
Present Value
Discounted (@ 10.18%)
73.61 59.64 58.51 59.73 60.97
Present value of next 5 years cash flows €312.45
OTCPK:TTAL.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= €99.00 × (1 + 2.73%) ÷ (10.18% – 2.73%)
€1,364.84
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= €1,364.84 ÷ (1 + 10.18%)5
€840.50
OTCPK:TTAL.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= €312.45 + €840.50
€1,152.95
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,152.95 / 128.04
€10.13
OTCPK:TTAL.F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:TTAL.F represents 1.12444x of HLSE:TTALO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.12444x
Value per Share
(Listing Adjusted, USD)
= Value per Share (EUR) x Listing Adjustment Factor
= € 9.00 x 1.12444
$10.13
Value per share (USD) From above. $10.13
Current discount Discount to share price of $9.55
= -1 x ($9.55 - $10.13) / $10.13
5.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Terveystalo Oyj is available for.
Intrinsic value
6%
Share price is $9.55 vs Future cash flow value of $10.13
Current Discount Checks
For Terveystalo Oyj to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Terveystalo Oyj's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Terveystalo Oyj's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Terveystalo Oyj's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Terveystalo Oyj's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:TTAL.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €0.54
HLSE:TTALO Share Price ** HLSE (2019-02-21) in EUR €8.49
United States of America Healthcare Industry PE Ratio Median Figure of 52 Publicly-Listed Healthcare Companies 21.37x
United States of America Market PE Ratio Median Figure of 3,045 Publicly-Listed Companies 17.39x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Terveystalo Oyj.

OTCPK:TTAL.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= HLSE:TTALO Share Price ÷ EPS (both in EUR)

= 8.49 ÷ 0.54

15.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Terveystalo Oyj is good value based on earnings compared to the US Healthcare industry average.
  • Terveystalo Oyj is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Terveystalo Oyj's expected growth come at a high price?
Raw Data
OTCPK:TTAL.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 15.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
7.7%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 39 Publicly-Listed Healthcare Companies 1.62x
United States of America Market PEG Ratio Median Figure of 2,118 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

OTCPK:TTAL.F PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 15.72x ÷ 7.7%

2.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Terveystalo Oyj is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Terveystalo Oyj's assets?
Raw Data
OTCPK:TTAL.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €4.00
HLSE:TTALO Share Price * HLSE (2019-02-21) in EUR €8.49
United States of America Healthcare Industry PB Ratio Median Figure of 91 Publicly-Listed Healthcare Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,129 Publicly-Listed Companies 1.87x
OTCPK:TTAL.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= HLSE:TTALO Share Price ÷ Book Value per Share (both in EUR)

= 8.49 ÷ 4.00

2.12x

* Primary Listing of Terveystalo Oyj.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Terveystalo Oyj is good value based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Terveystalo Oyj's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Terveystalo Oyj has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Terveystalo Oyj expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Terveystalo Oyj expected to grow at an attractive rate?
  • Terveystalo Oyj's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Terveystalo Oyj's earnings growth is positive but not above the United States of America market average.
  • Terveystalo Oyj's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:TTAL.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:TTAL.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 7.7%
OTCPK:TTAL.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 9.1%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 15.9%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:TTAL.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:TTAL.F Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,228 98 1
2022-12-31 1,150 84 2
2021-12-31 1,077 121 70 4
2020-12-31 1,049 113 60 5
2019-12-31 1,001 114 52 4
OTCPK:TTAL.F Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 745 101 69
2018-09-30 737 100 65
2018-06-30 732 84 42
2018-03-31 727 82 29
2017-12-31 690 70 7
2017-09-30 646 73 9
2017-06-30 610 81 16
2017-03-31 567 62 16
2016-12-31 547 65 13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Terveystalo Oyj's earnings are expected to grow by 7.7% yearly, however this is not considered high growth (20% yearly).
  • Terveystalo Oyj's revenue is expected to grow by 9.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:TTAL.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Terveystalo Oyj Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:TTAL.F Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.77 0.77 0.77 1.00
2022-12-31 0.56 0.66 0.46 2.00
2021-12-31 0.52 0.57 0.42 4.00
2020-12-31 0.45 0.51 0.39 4.00
2019-12-31 0.41 0.42 0.39 3.00
OTCPK:TTAL.F Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 0.54
2018-09-30 0.53
2018-06-30 0.34
2018-03-31 0.24
2017-12-31 0.06
2017-09-30 0.07
2017-06-30 0.02
2017-03-31 0.14
2016-12-31 0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Terveystalo Oyj is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Terveystalo Oyj's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Terveystalo Oyj has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Terveystalo Oyj performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Terveystalo Oyj's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Terveystalo Oyj has delivered over 20% year on year earnings growth in the past 5 years.
  • Terveystalo Oyj's 1-year earnings growth exceeds its 5-year average (854.2% vs 95.8%)
  • Terveystalo Oyj's earnings growth has exceeded the US Healthcare industry average in the past year (854.2% vs 17.5%).
Earnings and Revenue History
Terveystalo Oyj's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Terveystalo Oyj Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:TTAL.F Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 744.70 68.70 45.30
2018-09-30 736.70 64.70 45.10
2018-06-30 731.80 41.80 44.60
2018-03-31 726.50 28.60 52.90
2017-12-31 689.50 7.20 41.80
2017-09-30 646.10 8.70 38.20
2017-06-30 609.90 16.34 34.79
2017-03-31 566.85 16.27 22.30
2016-12-31 547.00 12.60 30.00
2015-12-31 505.62 1.11 30.59
2014-12-31 474.13 -82.90 29.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Terveystalo Oyj has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Terveystalo Oyj used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.
  • Terveystalo Oyj has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Terveystalo Oyj's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Terveystalo Oyj has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Terveystalo Oyj's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Terveystalo Oyj's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Terveystalo Oyj's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Terveystalo Oyj's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Terveystalo Oyj's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Terveystalo Oyj Company Filings, last reported 1 month ago.

OTCPK:TTAL.F Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 511.80 450.20 36.90
2018-09-30 502.20 290.00 79.40
2018-06-30 493.00 289.60 71.50
2018-03-31 493.00 290.00 43.60
2017-12-31 457.30 289.40 33.00
2017-09-30 326.90 383.50 5.70
2017-06-30 333.77 384.52 20.37
2017-03-31 232.20 347.20 39.10
2016-12-31 232.20 347.20 39.10
2015-12-31 220.38 352.33 16.62
2014-12-31 218.48 328.16 19.90
  • Terveystalo Oyj's level of debt (88%) compared to net worth is high (greater than 40%).
  • Unable to establish if Terveystalo Oyj's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (22.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 8.9x coverage).
X
Financial health checks
We assess Terveystalo Oyj's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Terveystalo Oyj has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Terveystalo Oyj's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.36%
Current annual income from Terveystalo Oyj dividends. Estimated to be 3.4% next year.
If you bought $2,000 of Terveystalo Oyj shares you are expected to receive $47 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Terveystalo Oyj's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.4%).
  • Terveystalo Oyj's dividend is below the markets top 25% of dividend payers in United States of America (3.54%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:TTAL.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 1.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2001 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:TTAL.F Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 0.45 1.00
2022-12-31 0.40 1.00
2021-12-31 0.33 3.00
2020-12-31 0.26 4.00
2019-12-31 0.22 4.00
OTCPK:TTAL.F Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-02-14 0.200 2.348
2018-04-12 0.060 0.669

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • It is too early to tell whether Terveystalo Oyj has stable dividend payments.
  • Terveystalo Oyj only just started paying a dividend, it is too early to tell if payments are increasing.
Current Payout to shareholders
What portion of Terveystalo Oyj's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.7x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.8x coverage).
X
Income/ dividend checks
We assess Terveystalo Oyj's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Terveystalo Oyj afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Terveystalo Oyj has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Terveystalo Oyj's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yrjö Närhinen
AGE 49
TENURE AS CEO 9.1 years
CEO Bio

Mr. Yrjö Närhinen has been the Chief Executive Officer of Terveystalo Oyj since 2010. Mr. Narhinen serves as Managing Director of Hartwall Ltd, SCOY Holding Oy, Gillette Group Finland Oy, Helepark Oy and Lapin Kulta Oy as well as held various managerial positions at Procter & Gamble, including a position as the Country Manager for Norway and Finland. Mr. Narhinen serves as the Chairman of the Board of Directors of Lääkäripalveluyritykset ry. He served as Chairman of the Board of Directors of Terveyspalvelualan Tieto Oy (currently Hyvinvointialan Tieto Oy). He serves as the Vice Chairman of the Board of Directors of Hyvinvointialan liitto ry, a member of the Boards of Directors of Hyvinvointialan Tieto Oy, Närhen pesä Oy, Kuntopolku Oy, Kuntoutumis- ja liikuntasäätiö Peurunka sr, Martela Corporation, LPY-Koulutus Oy and Teijon Masuuni Oy. as well as a member of the Board of Directors of Mathildedal’s Brewery Ltd. He holds a Bachelor of Science degree in Economics and Business Administration from the Helsinki School of Economics.

CEO Compensation
  • Insufficient data for Yrjö to compare compensation growth.
  • Insufficient data for Yrjö to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Terveystalo Oyj management team in years:

3.1
Average Tenure
48
Average Age
  • The tenure for the Terveystalo Oyj management team is about average.
Management Team

Yrjö Närhinen

TITLE
Chief Executive Officer
AGE
49
TENURE
9.1 yrs

Ilkka Laurila

TITLE
Chief Financial Officer
AGE
41
TENURE
4.1 yrs

Kati Kaksonen

TITLE
Director of Investor Relations & Financial Communications

Julia Ormio

TITLE
Senior Vice President of Legal
AGE
48
TENURE
0.2 yrs

Susanna Kinnari

TITLE
Senior Vice President of Communications
AGE
51
TENURE
4.1 yrs

Johanna Karppi

TITLE
Senior Vice President of HR
AGE
50
TENURE
12.1 yrs

Jens Jensen

TITLE
Senior Vice President of Commercial
AGE
45
TENURE
3.1 yrs

Juha Juosila

TITLE
Chief Digital Officer
AGE
46
TENURE
3.1 yrs

Laura Räty

TITLE
Senior Vice President of Public Partnerships
AGE
41
TENURE
3.1 yrs

Siina Saksi

TITLE
Chief Operating Officer of Clinic Network
AGE
52
TENURE
3.1 yrs
Board of Directors Tenure

Average tenure and age of the Terveystalo Oyj board of directors in years:

2.1
Average Tenure
52
Average Age
  • The average tenure for the Terveystalo Oyj board of directors is less than 3 years, this suggests a new board.
Board of Directors

Fredrik Cappelen

TITLE
Chairman
AGE
61
TENURE
6.1 yrs

Tom Von Rettig

TITLE
Vice Chairman
AGE
38
TENURE
0.8 yrs

Lasse Heinonen

TITLE
Director
AGE
50

Olli Holmström

TITLE
Director
AGE
58
TENURE
2.1 yrs

Vesa Koskinen

TITLE
Director
AGE
39
TENURE
6.1 yrs

Åse Michelet

TITLE
Director
AGE
66
TENURE
3.1 yrs

Eeva Ahdekivi

TITLE
Director
AGE
52
TENURE
1.1 yrs

Katri Viippola

TITLE
Director
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Terveystalo Oyj's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Terveystalo Oyj has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Map
Description

Terveystalo Oyj provides healthcare services in Finland. The company offers versatile and occupational healthcare, and medical and examination services; and laboratory, imaging, and other diagnosis services, as well as insurance and clinical research services through approximately 180 clinics. It serves private individuals, companies and communities, insurance companies, and public sector customers. The company is based in Helsinki, Finland.

Details
Name: Terveystalo Oyj
TTAL.F
Exchange: OTCPK
Founded:
€1,232,041,424
128,036,531
Website: http://www.terveystalo.com
Address: Terveystalo Oyj
Jaakonkatu 3 B,
3rd Floor,
Helsinki,
Uusimaa, 00100,
Finland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
HLSE TTALO Common Shares OMX Nordic Exchange Helsinki FI EUR 11. Oct 2017
OTCPK TTAL.F Common Shares Pink Sheets LLC US USD 11. Oct 2017
DB 4TS Common Shares Deutsche Boerse AG DE EUR 11. Oct 2017
LSE 0RV1 Common Shares London Stock Exchange GB EUR 11. Oct 2017
Number of employees
Current staff
Staff numbers
6,018
Terveystalo Oyj employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/22 01:21
End of day share price update: 2019/02/21 00:00
Last estimates confirmation: 2019/02/20
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.